Sign in Subscribe
Drugs

ImmunoCellular Therapeutics Enters Option Agreement with University of Texas M. D. Anderson Cancer Center

Strategic Insights

— 1 min read

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center regarding an immunotherapy targeting cancer stem cells (CSCs). This new therapy has shown significant promise in pre-clinical animal models, targeting and destroying CSCs. The agreement bolsters ImmunoCellular's portfolio of technologies targeting CSCs, including ICT-107, a dendritic cell-based immunotherapy that recently completed a phase I study, and ICT-121, an off-the-shelf peptide targeting CSCs.

Key Takeaways:

  • ImmunoCellular Therapeutics has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center for an immunotherapy targeting cancer stem cells (CSCs).
  • The therapy, developed by Dr. Constantin G. Ioannides and Satoko Matsueda, targets abnormal Notch and Numb pathways implicated in solid tumors such as breast, colon, and ovarian cancers.
  • The immunotherapy has demonstrated significant ability to target and destroy CSCs in pre-clinical animal models.
  • The therapy has shown promise in targeting cancer stem cells derived from breast cancer, ovarian cancer, and pancreatic cancer.
  • The immunotherapy has been demonstrated to express on clinical samples from ovarian cancer patients.
  • ImmunoCellular Therapeutics' portfolio now includes ICT-107, a dendritic cell-based immunotherapy, and ICT-121, an off-the-shelf peptide targeting CSCs.

Statistics:

  • 2 mechanisms (Notch and Numb pathways) implicated in many common solid tumors including breast, colon, and ovarian cancers.
  • 3 types of cancers targeted by the immunotherapy: breast cancer, ovarian cancer, and pancreatic cancer.
  • 1 phase II study conducted evaluating the E75 peptide targeting Her-2/neu.
  • 100% expression of the peptides demonstrated on clinical samples from ovarian cancer patients.

Sources:

  • Cancer Weekly editors
  • NewsRx.com
  • ImmunoCellular Therapeutics, Ltd. press release.

Read more